Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 14379 for:    Hemorrhage AND blood loss

The Effectiveness of Ankaferd Blood Stopper in the Management of Traumatic Bleeding

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03871452
Recruitment Status : Completed
First Posted : March 12, 2019
Last Update Posted : March 12, 2019
Sponsor:
Information provided by (Responsible Party):
nazmiye koyuncu, Haydarpasa Numune Training and Research Hospital

Brief Summary:

The objective of this study was to prospectively compare effectiveness of Ankaferd Blood Stopper (ABS) with dry sponges in cessation of bleeding in adult trauma cases with external bleeding due to extremity lacerations.

Methods: The study was conducted on patients with bleeding associated with extremity lacerations. All consecutive patients presented to the emergency department of the high-volume training hospital in Istanbul were recruited within the study period


Condition or disease Intervention/treatment Phase
Bleeding Disorder Procedure: Ankaferd Blood Stopper in theTraumatic Bleeding Not Applicable

Detailed Description:

This study was planned as a prospective randomized study. After local ethics committee approval, all consecutive patients admitted to the Emergency Department of the Haydarpasa Numune Training & Research Hospital due to extremity lacerations between October 1st and October 11th 2018 were recruited. The longest duration for wound healing, infection follow-up, and suture removal was 12 days. Therefore, the study was completed in a total of 23 days after suture removal of the last case.

ABS which was approved in 2017 by the Ministry of Health, is being used routinely in the management of the patients with traumatic bleeding in the emergency department of the hospital. Nurses working in treatment areas of the department were trained for this prospective study. They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.

The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses (group II). Demographic data, systemic disease history, drugs used, injury mechanism, habits etc. of the patients enrolled in the study were recorded into data collection form.

Forty commercially prepared ABS-soaked wet sterile sponges and 40 dry sponges of 2.5x7 cm were randomly numbered and placed in a box in the study area. Random numbers table was used to generate the sequence of enumeration of the sponges. Any given patient was treated with the next sponge with the smallest number in the box and data sheets contained the number of the sponge with which the patient's bleeding was intervened. Therefore, allocation concealment was accomplished for the study purposes.

In both groups, lacerations that did not stop bleeding within 10 minutes and lacerations with recurred bleeding within the half-hour follow-up period were repaired by the primary suturing. Lacerations were sutured at the end of follow-up period in other patients. Daily dressing was recommended to the patients at discharge, and they were invited for a follow-up visit 3 days later. They were followed-up for wound infection. Suture removal date was recorded in data collection form.

Statistical analysis was conducted by using the MedCalc Statistical Software version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2013). Descriptive statistics were used to define continuous variables in this study (mean, standard deviation, range, and median). Mann Whitney U test was used to compare two independent and abnormally distributed groups. Chi-square test was performed to compare categorical variables, or Fisher's Exact test was performed where appropriate or required. Statistical significance level was determined as p<0.05.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The study was conducted on patients with bleeding associated with extremity lacerations. All consecutive patients presented to the emergency department of the high-volume training hospital in Istanbul were recruited within the study period
Masking: None (Open Label)
Masking Description: I don't understand very well.
Primary Purpose: Health Services Research
Official Title: Haydarpaşa Numune Education and Research Hospital
Actual Study Start Date : October 1, 2018
Actual Primary Completion Date : October 11, 2018
Actual Study Completion Date : October 23, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bleeding

Arm Intervention/treatment
Active Comparator: ABS in external bleeding
Drug Ankaferd Blood Stopper Bleeding control in 10 minutes with ABS
Procedure: Ankaferd Blood Stopper in theTraumatic Bleeding

ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.

The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses


Active Comparator: Repetition of ABS stopped bleeding
Repetition of ABS stopped bleeding
Procedure: Ankaferd Blood Stopper in theTraumatic Bleeding

ankaferd blood stpper They were trained to apply compression of approximately 3-kg weight after irrigation with saline in patients with active bleeding who met inclusion criteria. Bleeding was controlled in every minute and data were collected. Traditional methods such as primary suturing were performed in patients whose bleeding did not stop within 10 minutes. Patients whose bleeding was stopped were monitored for half an hour for bleeding recurrence.

The patients were divided into two groups; ones treated by ABS soaked wet compresses (group I) and ones treated by dry sponge compresses





Primary Outcome Measures :
  1. Bleeding control [ Time Frame: 1-10 minute ]
    Group I were compressed with ABS-soaked wet sponge, and group II were treated with compression using dry sterile sponges. The compresses were briefly removed at one-minute intervals and bleeding status were checked. This process was continued for a maximum of 10 minutes. The time when both stopped the bleeding was noted for comparison.The main issue here was to see how long the ABS had taken control of the bleeding

  2. Repetition of bleeding [ Time Frame: 0-30 minute ]
    Wounds were monitored for half an hour for bleeding recurrence


Secondary Outcome Measures :
  1. Wound infection [ Time Frame: 3-5 days ]
    They were invited for a follow-up visit 3 days later for wound infection


Other Outcome Measures:
  1. Suture removal [ Time Frame: 8-12 days ]
    Suture removal date was recorded in data collection form.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adult patients (18 years-old and above)
  • presented with isolated cuts on the extremities
  • cuts sized between 1 and 5 centimeters .

Exclusion Criteria:

  • Patients under 18 years of age
  • with only superficial abrasions
  • with lacerations smaller than 1 cm and larger than 5 cm
  • irregular laceration borders or star-like lacerations
  • deep lacerations requiring subcutaneous suturing
  • lacerations requiring additional interventions such as tendon repair controlled bleeding
  • grade III and IV systemic diseases (advanced heart failure, uncontrolled hypertension, etc.) according to American Society of Anesthesiologists (ASA) classification,
  • who received radiotherapy or chemotherapy for malignancies within the last three months
  • with the history of hematologic diseases such as leukemia
  • using medications leading to hemorrhage risk (oral anticoagulants, aspirin, etc.)
  • congenital coagulation factor deficiency such as hemophilia
  • multiple trauma and abnormal vital signs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03871452


Locations
Layout table for location information
Turkey
Nazmiye Koyuncu
Istanbul, Turkey, 0620
Sponsors and Collaborators
Haydarpasa Numune Training and Research Hospital
Investigators
Layout table for investigator information
Principal Investigator: Cagatay Nuhoglu, MD Haydarpasa Numune Education and Research Hospital/İSTANBUL/TURKEY

Publications of Results:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: nazmiye koyuncu, specialist of emergency medicine, Haydarpasa Numune Training and Research Hospital
ClinicalTrials.gov Identifier: NCT03871452     History of Changes
Other Study ID Numbers: h8w67r3k
First Posted: March 12, 2019    Key Record Dates
Last Update Posted: March 12, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by nazmiye koyuncu, Haydarpasa Numune Training and Research Hospital:
Ankaferd BloodStopper, laceration, bleeding

Additional relevant MeSH terms:
Layout table for MeSH terms
Hemorrhage
Blood Coagulation Disorders
Hemostatic Disorders
Pathologic Processes
Hematologic Diseases
Vascular Diseases
Cardiovascular Diseases
Hemorrhagic Disorders